Photocure is pleased to announce that the Pharmaceutical Benefits Board in Sweden (LFN) has decided that Metvix photodynamic therapy (PDT) shall be fully reimbursed for premalignant skin cancer (actinic keratosis (AK)) non-melanoma skin cancer and Bowen's disease. Metvix PDT is an effective non-invasive treatment approved for the treatment of certain cancerous and precancerous skin lesions and registered in approximately 30 countries worldwide, including the majority of European countries, Australia and New Zealand.
Photocure will thoroughly evaluate how this decision can positively influence reimbursement and patient access in the other Nordic countries.
Kjetil Hestdal MD. Ph.D., President and CEO of Photocure comments: "The Pharmaceutical Benefits Board in Sweden (LFN) is known as one of the most rigorous evaluators of health and economic benefits of new medical treatments. As such, we are very pleased that Metvix PDT has been granted full reimbursement for treating AK and non-melanoma skin cancer in Sweden as it validates the way we work at Photocure, providing new and effective treatment to patients with a defined medical need at a price that also provides good value to society. We will continue to pursue Metvix PDT reimbursement possibilities in the Nordic region. " Read more at www.photocure.no
Photocure ASA is a Norwegian pharmaceutical listed on Oslo Stock Exchange. The company develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technologies, targeting key dermatology and oncology markets.